Nomograms in the era of personalized oncologic surgery

Abstract

Colorectal cancer remains a leading cause of cancer mortality, and the development of liver metastases represents a pivotal determinant of prognosis. Despite advances in systemic therapy and surgical techniques, survival after liver resection for colorectal liver metastases (CRLM) remains highly variable. The study by Xie et al addresses this challenge by proposing a clinically applicable nomogram that integrates biochemical parameters (γ-glutamyl transferase, chloride, activated partial thromboplastic time) with tumor-related factors (N stage, vascular invasion) to improve overall survival prediction. Using a large single-center cohort of 1059 surgically treated CRLM patients, the authors applied LASSO-Cox regression to identify independent prognostic variables. The resulting model demonstrated strong predictive accuracy in both training and validation cohorts, with decision curve analysis confirming its clinical utility. By combining tumor biology with systemic and host-related factors, the nomogram reflects a multidimensional approach to prognosis and highlights the value of routinely available laboratory markers, enhancing feasibility in real-world and resource-limited settings. Nevertheless, external validation in diverse populations and contemporary treatment contexts remains essential before widespread implementation. This work illustrates the ongoing transition toward personalized, data-driven decision-making in surgical oncology. The proposed model may assist in preoperative risk stratification, tailoring surveillance strategies, guiding adjuvant therapy, and supporting shared decision-making. Further integration of molecular biomarkers and advanced imaging features could enhance its prognostic precision and facilitate translation into routine clinical practice.

Key Words: Nomogram; Colorectal cancer; Liver metastases; Cancer treatment; Prognostic model; Surgical treatment; Long term outcomes

Core Tip: Personalized oncology increasingly depends on integrating quantitative tools into clinical decision-making. The study by Xie et al introduces a nomogram that combines tumor- and host-related factors (including γ-glutamyl transferase, chloride, activated partial thromboplastic time, N stage, and vascular invasion) to predict survival after colorectal liver metastasis resection. Unlike traditional scores such as Fong or Nordlinger models, this LASSO-Cox–based approach reflects biologic and systemic determinants of outcome. Accessibility and interpretability make it promising for daily surgical oncology practice, emphasizing the ongoing shift toward precision-guided, individualized care in metastatic colorectal cancer.

INTRODUCTION

Colorectal cancer (CRC) remains one of the leading causes of death in oncology, with hepatic metastases representing the most common and clinically significant site of distant spread. Although there has been a slow decline in overall incidence, in the younger patients incidence is increasing[1]. Surgical resection of colorectal liver metastases (CRLM) offers the best chance for long-term survival in selected cases, but outcomes are heterogeneous, with a mean survival between 2.5 years and 3.8 years[2]. Identifying the patients who stand to benefit most from surgery and who may require intensified or alternative strategies continues to challenge clinicians, and better tools are needed to predict outcome.

In this context, the recently published study by Xie et al[3] presents an important step toward individualized care: The development and validation of a nomogram-based survival prediction model for patients undergoing hepatic resection for CRLM.

STUDY OVERVIEW

The study’s investigators analyzed a large, single-center cohort of 1059 patients treated between 2010 and 2022 at Xijing Hospital (Xi’an, China). Using a combination of LASSO regression and Cox proportional hazards modeling, they identified five key prognostic variables significantly linked to CRLM: γ-glutamyl transferase (GGT), blood chloride concentration, activated partial thromboplastin time (aPTT), N stage, and vascular invasion.

These factors were integrated into a nomogram that achieved a significant area under the receiver operating characteristic curve in both training and validation (internal) cohorts, demonstrating solid discrimination. Decision curve analysis supported the model’s clinical utility, and Kaplan-Meier analysis confirmed clear survival separation between predicted high- and low-risk groups.

Context and significance

Traditional CRLM prognostic models, such as the Fong Clinical Risk Score (FCRS) or Nordlinger score, were built over two decades ago, based largely on clinicopathologic parameters: Tumor size, number of metastases, disease-free interval, and carcinoembryonic antigen (CEA) levels.

The FCRS, introduced in 1999 by Fong et al[4] from Memorial Sloan Kettering Cancer Center, remains one of the most widely recognized and validated models for predicting outcomes after resection of CRLM. Using multivariate analysis, the authors identified five independent adverse prognostic factors significantly associated with decreased overall survival. Each factor was assigned one point, producing a five-point scoring system: Preoperative CEA level (> 200 ng/mL), disease-free interval from diagnosis of primary tumor to discovery of liver metastasis (< 12 months), number of hepatic metastases (> 1), largest liver metastasis diameter (> 5 cm), and lymph node status of primary tumor (positive). In the aggressive-approach era of surgery, FCRS remains a critical tool in patient selection for hepatectomy and estimation of prognosis after liver resection. FCRS has been validated in many trials[5,6]. Although widely adopted and historically influential, it showed only moderate predictive accuracy in contemporary cohorts. Similarly, the Nordlinger score, which integrates parameters such as metastasis number and size, disease-free interval, and resection margin, performed inconsistently across risk groups, often overestimating mortality in patients receiving modern multimodal therapy. The Ishizuka score, which included systemic inflammatory markers (e.g., C-reactive protein, neutrophil-to-lymphocyte ratio), showed potential but lacked standardization in measurement and cut-off values[7].

Gomez and Cameron[8] and Reissfelder et al[9] highlighted that such tools frequently oversimplify complex biological processes by focusing solely on static clinical or pathological variables while ignoring dynamic factors such as tumor biology, treatment response, and molecular profiling. The authors advocated for the development of adaptive, biologically integrated models—a concept that aligns closely with the modern nomogram-based approach.

The nomogram proposed by Xie et al[3] reflects a more contemporary conceptual framework in CRLM prognostication. Rather than relying solely on tumor burden metrics, the model integrates a combination of tumor-related factors (N stage and vascular invasion) and biochemical parameters reflecting host physiology and systemic status (GGT, chloride levels, and aPTT). This approach acknowledges that survival outcomes after hepatic resection are influenced not only by tumor biology but also by the underlying metabolic and hemostatic milieu, perioperative resilience, and organ function reserve.

Importantly, the use of LASSO-Cox regression represents a methodological improvement over traditional multivariate approaches, allowing for more refined variable selection and reduction of overfitting. This strengthens the model’s internal validity and enhances its discriminatory precision. Decision curve analysis further supports its potential clinical value, demonstrating a higher net benefit across clinically relevant threshold probabilities compared with conventional stratification strategies.

Strengths and limitations

The study’s large sample size and internal validation lend weight to its conclusions. However, several caveats merit consideration. The cohort was derived from a single institution, raising concerns about generalizability across ethnic and treatment backgrounds. The model lacks external validation in independent datasets, a crucial step before clinical implementation. Variations in surgical technique, perioperative protocols, patient selection criteria, and systemic treatment strategies across institutions may significantly alter survival outcomes. As a result, the generalizability of this nomogram to broader populations, particularly Western cohorts or centers with different therapeutic algorithms, remains uncertain without independent external validation. Furthermore, emerging biomarkers, such as RAS/BRAF mutational status, microsatellite instability (MSI), and circulating tumor DNA (ctDNA), as well as data regarding systemic treatments, were not included, though they profoundly influence survival and recurrence risk. Another important limitation is the static nature of the model. Prognosis in CRLM is dynamic and influenced by treatment response, disease evolution, and perioperative complications. The nomogram provides a single time-point prediction and does not account for temporal changes in tumor burden, biochemical parameters, or response to neoadjuvant therapy.

In parallel, with the refinement of surgical techniques and prognostic modeling, advances in systemic therapy have profoundly altered the natural history of CRLM. Multiple landmark trials, such as EORTC 40983[10], CAIRO5[11], and CELIM[12] have demonstrated that the addition of modern chemotherapy and targeted agents can downsize initially unresectable lesions, thereby increasing the likelihood of achieving R0 resection and significantly improving survival outcomes. In addition, immunotherapy can achieve outstanding results. The concept of conversion therapy, transforming metastatic disease from unresectable to operable, has redefined treatment goals and challenged the static assumptions of earlier prognostic scores. Moreover, perioperative chemotherapy has been shown to improve disease-free survival and may better identify patients with favorable tumor biology who would benefit the most from surgery[13]. Nevertheless, the work provides an updated, data-driven tool that may be readily applicable in daily surgical oncology practice.

Future directions

The integration of systemic treatment and molecular predictors represents the logical next frontier in CRLM prognostication, in the context of a multidisciplinary treatment approach. Biomarkers such as RAS and BRAF mutations, MSI status, and ctDNA provide powerful insights into tumor aggressiveness, treatment sensitivity, and recurrence risk. These parameters could be incorporated as weighted variables within expanded nomogram algorithms. Beyond single biomarkers, the integration of radiomics and transcriptomic or proteomic signatures would enable the development of composite risk profiles that reflect both phenotypic and genotypic tumor behavior. Machine learning–assisted nomograms may further refine prognostic accuracy by dynamically recalibrating risk estimates based on real-time treatment response and longitudinal biomarker evolution. Such approaches would transform nomograms from static prediction tools into adaptive systems capable of capturing the biological complexity of metastatic CRC, reinforcing their role as essential tools for personalized oncologic surgery.

As nomogram-based tools mature, their true value will lie not only in prognostic stratification but in their integration into everyday clinical workflows. In modern oncologic surgery, such models can serve as objective decision-support instruments during multidisciplinary tumor board discussions, helping to guide complex decisions regarding surgical candidacy, timing of hepatectomy, and the selection of neoadjuvant or conversion therapy. By providing individualized survival estimates, nomograms also enhance patient counseling, facilitating transparent communication of risk–benefit profiles and fostering shared decision-making. From a translational perspective, embedding these models into electronic health records could enable real-time, automated risk calculation based on routinely collected data, transforming them from static academic tools into dynamic instruments guiding perioperative strategy. Ultimately, this integration may allow surgeons and oncologists to tailor therapeutic intensity, surveillance protocols, and follow-up scheduling with greater precision, aligning surgical practice with the principles of personalized oncology.

CONCLUSION

The nomogram proposed by Xie et al[3] represents a meaningful step toward more accurate and individualized survival prediction in CRLM surgery. While further external validation and incorporation of molecular data are needed, the study demonstrates how quantitative modeling can complement clinical judgment and enhance patient selection. Within the broader landscape of precision medicine, nomograms have the potential to serve as practical bridges between traditional surgical decision-making, molecular oncology, and emerging digital health technologies. As hepatobiliary surgeons and oncologists move deeper into the era of personalized care, such tools will play an increasingly important role in guiding evidence-based, patient-centered treatment strategies.